Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Samsung Epis Holdings
Incheon, South Koreasamsungepisholdings.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Samsung Epis Holdings was formed as a spin-off from Samsung Biologics in 2025 and is now the parent company overseeing Samsung Bioepis and Epis NexLab, both focused on biosimilars, innovative biologics and platform technologies; its main subsidiary Samsung Bioepis has commercialized 11 biosimilars and aims to expand to over 20 assets, covering immunology, oncology, ophthalmology, and hematology, with strong clinical evidence and global access
- Therapeutic areas
- OncologyImmunologyOphthalmologyGastroenterology
- Modalities
- Monoclonal antibodyBispecific monoclonal antibodyAntibody-drug conjugatePeptidesBiologic
- Industry
- Pharma
02
Partnerships
Biogen (development and commercialization)Organon (commercialization, ex-US Merck spinoff)SandozTevaTakeda (co-development of novel biologics)3SBio (regional China)CBC Group/AffaMed Therapeutics (regional China)Mundipharma (Hong Kong and Taiwan)BionovisBio-Manguinhos (Brazil)
Beyond the preview
Go deeper on Samsung Epis Holdings.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Samsung Epis Holdings.